Summary
74.62 0.17(0.22%)05/16/2024
Boston Scientific Corp. (BSX)
Boston Scientific Corp. (BSX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.22 | 2.16 | 6.88 | 12.56 | 40.74 | 38.22 | 99.69 | 1,615.04 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 73.43 | |
| Open | 72.70 | |
| High | 73.50 | |
| Low | 72.63 | |
| Volume | 3,153,128 | |
| Change | 0.89 | |
| Change % | 1.22 | |
| Avg Volume (20 Days) | 6,611,385 | |
| Volume/Avg Volume (20 Days) Ratio | 0.48 | |
| 52 Week Range | 48.35 - 74.39 | |
| Price vs 52 Week High | -1.30% | |
| Price vs 52 Week Low | 51.86% | |
| Range | 1.00 | |
| Gap Up/Down | -0.57 | |
Fundamentals | ||
| Market Capitalization (Mln) | 109,455 | |
| EBIDTA | 3,744,000,000 | |
| PE Ratio | 61.9244 | |
| PEG Ratio | 1.7987 | |
| WallStreet Target Price | 81.86 | |
| Book Value | 13.1550 | |
| Earnings Per Share | 1.1900 | |
| EPS Estimate Current Quarter | 0.5100 | |
| EPS Estimate Next Quarter | 0.5600 | |
| EPS Estimate Current Year | 2.3300 | |
| EPS Estimate Next Year | 2.6400 | |
| Diluted EPS (TTM) | 1.1900 | |
| Revenues | ||
| Profit Marging | 0.1206 | |
| Operating Marging (TTM) | 0.1888 | |
| Return on asset (TTM) | 0.0454 | |
| Return on equity (TTM) | 0.0925 | |
| Revenue TTM | 14,707,000,320 | |
| Revenue per share TTM | 10.0650 | |
| Quarterly Revenue Growth (YOY) | 0.1380 | |
| Quarterly Earnings Growth (YOY) | 0.5790 | |
| Gross Profit (TTM) | 8,679,000,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 61.9244 | |
| Forward PE | 30.2115 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.1893 | |
| Revenue Enterprise Value | 7.6322 | |
| EBITDA Enterprise Value | 31.5388 | |
| Shares | ||
| Shares Outstanding | 1,470,179,968 | |
| Shares Float | 1,462,180,857 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.20 | |
| Institutions (%) | 94.85 | |
05/16 12:15 EST - accesswire.com
Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation (BSX) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Boston Scientific Corporation (NYSE:BSX). The settlement provides for a fund of $38,500,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation (BSX) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Boston Scientific Corporation (NYSE:BSX). The settlement provides for a fund of $38,500,000 to benefit class members.
05/15 10:45 EST - zacks.com
3 Solid Buys From MedTech Following 2024 Guidance Raise
Guidance hikes by BSX, ALGN and ALC for 2024 make them attractive investment bets.
3 Solid Buys From MedTech Following 2024 Guidance Raise
Guidance hikes by BSX, ALGN and ALC for 2024 make them attractive investment bets.
05/15 10:32 EST - zacks.com
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
05/14 13:16 EST - zacks.com
Boston Scientific (BSX) Gains From MedSurg Growth & Buyouts
Within Neuromodulation, Boston Scientific's pain business is consistently gaining traction, banking on strength in the spinal cord stimulation (SCS) business.
Boston Scientific (BSX) Gains From MedSurg Growth & Buyouts
Within Neuromodulation, Boston Scientific's pain business is consistently gaining traction, banking on strength in the spinal cord stimulation (SCS) business.
05/08 16:00 EST - prnewswire.com
Boston Scientific Elects Dr. Cheryl Pegus to Board of Directors
MARLBOROUGH, Mass. , May 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Cheryl Pegus to its board of directors, effective immediately.
Boston Scientific Elects Dr. Cheryl Pegus to Board of Directors
MARLBOROUGH, Mass. , May 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Cheryl Pegus to its board of directors, effective immediately.
05/06 09:31 EST - zacks.com
A Golden Opportunity to Enter U.S. Stock Markets: 5 Top Picks
We have narrowed our search to five U.S. corporate behemoths that have strong growth potential for 2024. These are: GOOGL, NFLX, AMZN, NOW, BSX.
A Golden Opportunity to Enter U.S. Stock Markets: 5 Top Picks
We have narrowed our search to five U.S. corporate behemoths that have strong growth potential for 2024. These are: GOOGL, NFLX, AMZN, NOW, BSX.
05/04 06:15 EST - investorplace.com
Citi Just Raised Its Price Target on These 3 Stocks
Many Wall Street investors keep a close eye on the opinions of major brokerages, such as Citigroup (NYSE: C ). Therefore, today we'll explore three promising growth stocks that have recently received a vote of confidence by means of increases in Citi price targets.
Citi Just Raised Its Price Target on These 3 Stocks
Many Wall Street investors keep a close eye on the opinions of major brokerages, such as Citigroup (NYSE: C ). Therefore, today we'll explore three promising growth stocks that have recently received a vote of confidence by means of increases in Citi price targets.
05/02 07:05 EST - investorplace.com
Needham Just Boosted Its Price Target on These 3 Stocks
It's not exactly an ideal time to be a stock market investor. The market is in correction territory, with many leading tech giants experiencing a pullback in prices.
Needham Just Boosted Its Price Target on These 3 Stocks
It's not exactly an ideal time to be a stock market investor. The market is in correction territory, with many leading tech giants experiencing a pullback in prices.
04/30 10:34 EST - marketbeat.com
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Medical device maker Boston Scientific Co.'s NYSE: BDX product portfolio encompasses a wide range of therapeutic areas, from cardiovascular, urology, and neuromodulation to endoscopy instruments and rhythm management. The medical sector company is acquiring rhythm modulation device maker Axonics Inc. NASDAQ: AXNX in the second half of 2024 as the FTC requests additional information on the deal.
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Medical device maker Boston Scientific Co.'s NYSE: BDX product portfolio encompasses a wide range of therapeutic areas, from cardiovascular, urology, and neuromodulation to endoscopy instruments and rhythm management. The medical sector company is acquiring rhythm modulation device maker Axonics Inc. NASDAQ: AXNX in the second half of 2024 as the FTC requests additional information on the deal.
04/29 10:46 EST - zacks.com
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
Here is how Boston Scientific (BSX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
Here is how Boston Scientific (BSX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
04/26 12:31 EST - zacks.com
3 Medical Products Stocks Set to Beat This Earnings Season
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
3 Medical Products Stocks Set to Beat This Earnings Season
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
04/26 10:55 EST - zacks.com
Here's Why Boston Scientific (BSX) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Boston Scientific (BSX) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
04/25 10:46 EST - zacks.com
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
04/24 13:41 EST - zacks.com
Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised
Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised
Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
04/24 12:41 EST - zacks.com
AHCO vs. BSX: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
AHCO vs. BSX: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
04/24 11:40 EST - investopedia.com
Boston Scientific Beats Forecasts, Boosts Outlook on Booming Heart Device Sales
Shares of Boston Scientific (BSX) hit an all-time high Wednesday as the maker of medical equipment reported better-than-anticipated quarterly results and boosted its guidance on demand for its cardiovascular devices, including a newly approved product to treat irregular heartbeats.
Boston Scientific Beats Forecasts, Boosts Outlook on Booming Heart Device Sales
Shares of Boston Scientific (BSX) hit an all-time high Wednesday as the maker of medical equipment reported better-than-anticipated quarterly results and boosted its guidance on demand for its cardiovascular devices, including a newly approved product to treat irregular heartbeats.
04/24 11:15 EST - seekingalpha.com
Boston Scientific Corporation (BSX) Q1 2024 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Q1 2024 Earnings Conference Call April 24, 2024 8:00 AM ET Company Participants Jon Monson - Senior Vice President, Investor Relations Mike Mahoney - Chairman and Chief Executive Officer Dan Brennan - Executive Vice President and Chief Financial Officer Ken Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Rick Wise - Stifel Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Travis Steed - Bank of America Danielle Antalffy - UBS Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Matthew O'Brien - Piper Sandler Matt Taylor - Jefferies Matt Miksic - Barclays Michael Polark - Wolfe Research Operator Good morning, and welcome to the Boston Scientific First Quarter 2024 Earnings Call. All participants will be in listen-only mode.
Boston Scientific Corporation (BSX) Q1 2024 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Q1 2024 Earnings Conference Call April 24, 2024 8:00 AM ET Company Participants Jon Monson - Senior Vice President, Investor Relations Mike Mahoney - Chairman and Chief Executive Officer Dan Brennan - Executive Vice President and Chief Financial Officer Ken Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Rick Wise - Stifel Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Travis Steed - Bank of America Danielle Antalffy - UBS Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Matthew O'Brien - Piper Sandler Matt Taylor - Jefferies Matt Miksic - Barclays Michael Polark - Wolfe Research Operator Good morning, and welcome to the Boston Scientific First Quarter 2024 Earnings Call. All participants will be in listen-only mode.